Mario Fernandez, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Tecnofarma
    Mitigation strategy: 
    Divest
    Relationship end date: 
    04/17/2023
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Grünenthal
    Mitigation strategy: 
    Attest
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Merck
    Mitigation strategy: 
    Divest
    Relationship end date: 
    11/11/2021
    Date reviewed: 
    07/25/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Ferring
    Mitigation strategy: 
    Divest
    Relationship end date: 
    09/09/2021
    Date reviewed: 
    07/25/2023
Return to Avances globales en el cáncer de vejiga (2023) - Español